Skip to main content

Table 6 Case-control comparison of NAT2 genotypes

From: Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study

 

Controls(N = 426)

Cases (N = 545)

    

NAT2 Genotype (phenotype)

n

%

n

%

OR

CI

p

q

NAT2*4/*4 (rapid)

19

4.5

42

7.7

1

   

NAT2*4/*5(intermediate)

108

25.4

116

21.3

0.49

0.26-0.88

0.021

0.168

NAT2*4/*6 (intermediate)

49

11.5

69

12.7

0.6

0.30-1.16

0.133

0.532

NAT2*4/*7 (intermediate)

4

0.9

13

2.4

1.43

0.43-5.65

0.576

1

NAT2*5/*6 (slow)

106

24.9

130

23.9

0.55

0.29-0.99

0.053

0.318

NAT2*5/*7 (slow)

5

1.2

10

1.8

0.86

0.26-3.10

0.809

1

NAT2*6/*6 (slow)

42

9.9

47

8.6

0.46

0.23-0.92

0.029

0.203

NAT2*6/*7 (slow)

5

1.2

7

1.3

0.56

0.15-2.21

0.394

1

NAT2*5/*5 (slow)

82

19.2

104

19.1

0.58

0.31-1.07

0.086

0.430

NAT2*5/*14 (slow)

1

0.2

0

0

--

--

--

 

NAT2*6/*14 (slow)

0

0

1

0.2

--

--

--

 

Missing

5

 

6

 

--

--

--

 
  1. Logistic regression analysis of individual NAT2 genotypes, adjusted for age. NAT2*4/*4 used as reference. OR = odds ratio; CI = 95% confidence intervals for ORs; p = p-value; q = q values for multiple testing adjustment using Holm's method. Overall chi-squared p = 0.25 (likelihood ratio test). Genotypes with 10 or less counts in either group (case or control) were not included in overall test of significance